The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs
Open accessAbstract
BACKGROUND: The efficacy and safety of anticoagulant treatment for patients with acute, symptomatic superficial-vein thrombosis in the legs, but without concomitant deep-vein thrombosis or symptomatic pulmonary embolism at presentation, have not been established. METHODS: In a randomized, double-blind trial, we assigned 3002 patients to receive either fondaparinux, administered subcutaneously at a dose of 2.5 mg once daily, or placebo for 45 days. The primary efficacy outcome was a composite of death from any cause or symptomatic pulmonary embolism, symptomatic deep-vein thrombosis, or symptomatic extension to the saphenofemoral junction or symptomatic recurrence of superficial-vein thrombosis at day 47. The main safety outcome was major bleeding. The patients were followed until day 77. RESULTS: The primary efficacy outcome occurred in 13 of 1502 patients (0.9%) in the fondaparinux group and 88 of 1500 patients (5.9%) in the placebo group (relative risk reduction with fondaparinux, 85%; 95% confidence interval [CI], 74 to 92; P<0.001). The incidence of each component of the primary efficacy outcome was significantly reduced in the fondaparinux group as compared with the placebo group, except for the outcome of death (0.1% in both groups). The rate of pulmonary embolism or deep-vein thrombosis was 85% lower in the fondaparinux group than in the placebo group (0.2% vs. 1.3%; 95% CI, 50 to 95; P<0.001). Similar risk reductions were observed at day 77. A total of 88 patients would need to be treated to prevent one instance of pulmonary embolism or deep-vein thrombosis. Major bleeding occurred in one patient in each group. The incidence of serious adverse events was 0.7% with fondaparinux and 1.1% with placebo. CONCLUSIONS: Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00443053.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa055443 · Cited by 1,228
Cohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649
Self-citationDentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Brandjes, D. P. M., Heijboer, H., Büller, H. R., de Rijk, M., Jagt, H., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272103 · Cited by 480
Superficial Venous Thrombosis and Venous Thromboembolism: A Large, Prospective Epidemiologic Study
Decousus, H., Quéré, I., Presles, E., Becker, F., Barrellier, M.-T., Chanut, M., Gillet, J.-L., Guenneguez, H., Leandri, C., Mismetti, P., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-4-201002160-00006 · Cited by 353
Self-citationEriksson, B. I. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1337 · Cited by 345
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Treatment for superficial thrombophlebitis of the leg
Di Nisio, M., Wichers, I. M., & Middeldorp, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004982.pub5 · Cited by 213
Self-citationVein abnormalities and the post‐thrombotic syndrome
PRANDONI, P., FRULLA, M., SARTOR, D., CONCOLATO, A., & GIROLAMI, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01106.x · Cited by 180
Self-citation(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1657 · Cited by 162
Superficial Thrombophlebitis of the Legs: A Randomized, Controlled, Follow-up Study
Belcaro, G. V., Nicolaides, A. N., Errichi, B. M., Cesarone, M. R., Sanctis, M. T. D., INCANDELA, L., Venniker, R., & Belcaro, G. (1999) · Angiology · doi:10.1177/000331979905000701 · Cited by 140
THE VESALIO INVESTIGATORS GROUP (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01391.x · Cited by 124
Superficial vein thrombosis: risk factors, diagnosis, and treatment
Decousus, H., Epinat, M., Guillot, K., Quenet, S., Boissier, C., & Tardy, B. (2003) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-200309000-00009 · Cited by 118
Self-citationMinno, G. D., Mannucci, P. M., Tufano, A., Palareti, G., Moia, M., Baccaglini, U., Rudelli, G., & Giudici, G. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01458.x · Cited by 97
Lozano, F. S., & Almazán, A. (2003) · Vascular and Endovascular Surgery · doi:10.1177/153857440303700605 · Cited by 91
Marchiori, A., Verlato, F., Sabbion, P., Camporese, G., Rosso, F., Mosena, L., Andreozzi, G. M., & Prandoni, P. (2002) · PubMed · Cited by 75
Self-citationManagement of Superficial Vein Thrombosis and Thrombophlebitis: Status and Expert Opinion Document
Cesarone, M. R., Belcaro, G., Agus, G. B., et al. (2007) · Angiology · doi:10.1177/0003319706297643 · Cited by 50
van Weert, H. C. P. M., Dolan, G., Wichers, I. M., de Vries, C., ter Riet, G., & Buller, H. R. (2006) · PubMed · Cited by 48
Maeseneer, M. G. D. (2005) · Acta chirurgica Belgica · doi:10.1080/00015458.2005.11679688 · Cited by 34
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Self-citationFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Metadata
- Authors
- Decousus, H., Prandoni, P., Mismetti, P., Bauersachs, R. M., Boda, Z., Brenner, B., Laporte, S., Matyas, L., Middeldorp, S., Sokurenko, G., & Leizorovicz, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-23
- Volume
- 363
- Issue
- 13
- Pages
- 1222-1232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143281433
- Cited by
- 402
- References
- 25
- FWCI
- 21.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.